Neurocrine price target raised to $160 from $150 at H.C. Wainwright

H.C. Wainwright analyst Andrew Fein raised the firm’s price target on Neurocrine to $160 from $150 and keeps a Buy rating on the shares. The firm says a 50% improvement in the PANSS scale compared to the control might get NBI-1117568 closer to the next-generation anti-psychotics.